Active Ingredient History
Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Carcinoma, Merkel Cell (Phase 1/Phase 2)
Carcinoma, Renal Cell (Phase 3)
Colorectal Neoplasms (Phase 1/Phase 2)
COVID-19 (Phase 1)
Melanoma (Phase 3)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 1/Phase 2)
Sarcoma (Phase 1/Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2/Phase 3)
Triple Negative Breast Neoplasms (Phase 1/Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue